VJHemOnc Podcast
By VJHemOnc
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by VJHemOnc
Category: Medicine
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 1
Reviews: 0
Episodes: 200
Description
The Video Journal of Hematology and Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjhemonc.com
| Episode | Date |
|---|---|
|
MPNs in focus: disease progression, risk assessment, and emerging treatments
|
Jun 15, 2026 |
|
The evolving role of cellular therapies and T-cell engagers in lymphoma
|
May 29, 2026 |
|
Multiple myeloma in 2026: MRD, BCMA therapies, CAR-T, and the path to cure
|
May 22, 2026 |
|
Dual-targeting CAR T-cell therapies in LBCL: efficacy, safety, and bridging therapy
|
May 15, 2026 |
|
Advances in gene-based therapies for SCD and thalassemia: access, outcomes & innovation
|
May 08, 2026 |
|
The evolving role of BTK inhibitors in CLL
|
May 01, 2026 |
|
Adverse events in the post-CAR T-cell therapy setting: infections, less common toxicities, and advice for physicians
|
Apr 24, 2026 |
|
The evolving treatment landscape in MCL: chemo-free strategies, BTK inhibitors, and changing standards of care
|
Apr 16, 2026 |
|
Advances in stem cell transplantation from EBMT 2026: managing GvHD, donor selection & evolving clinical strategies
|
Apr 09, 2026 |
|
Myeloid Monthly: breaking news & updates from the classification advancement meeting
|
Apr 02, 2026 |
|
How AI is transforming hematologic oncology
|
Mar 27, 2026 |
|
MRD in ALL and AML: from prognostic marker to clinical endpoint
|
Mar 20, 2026 |
|
Nursing in CAR-T & cellular therapy: updates and insights from the EBMT-EHA CAR T-cell Meeting 2026
|
Feb 27, 2026 |
|
Recent BTK inhibitor trial updates across non-Hodgkin lymphoma subtypes
|
Feb 20, 2026 |
|
ASH 2025 highlights in AL amyloidosis: risk stratification, bispecific antibodies, CAR-T, & MRD
|
Feb 06, 2026 |
|
Top ASH 2025 updates in AML: redefining frontline therapy, menin inhibition, venetoclax-based triplets, & emerging immunotherapies
|
Jan 30, 2026 |
|
Managing and preventing differentiation syndrome in APL
|
Jan 22, 2026 |
|
Top ASH 2025 NHL updates: novel CAR T-cell therapies, fixed-duration strategies, evolving frontline approaches, & more
|
Jan 16, 2026 |
|
Top updates in myeloma from ASH 2025: the RedirecTT-1 and MajesTEC-3 trials, dual-targeting CAR-T, trispecific antibodies, and more!
|
Jan 09, 2026 |
|
Top CLL updates from ASH 2025: novel BTKi monotherapy and combination approaches, BTK degraders, & more
|
Dec 18, 2025 |
|
Top updates in MDS from ASH 2025: key trial updates and debated topics
|
Dec 12, 2025 |
|
Sickle cell disease management: navigating the transition from pediatric to adult care, managing VOCs, & more
|
Nov 27, 2025 |
|
Accelerated- and blast-phase MPNs: diagnosis, management, and current challenges
|
Nov 20, 2025 |
|
The value and utility of MRD in the management of adults with newly-diagnosed AML
|
Nov 14, 2025 |
|
Updates from iwHRMM: targeted and immune-related therapies and mechanisms of resistance
|
Nov 07, 2025 |
|
Advances in immunotherapy for NHL: updates from iwNHL 2025
|
Oct 31, 2025 |
|
Reviewing recent guideline updates on the risk stratification and treatment of AML
|
Oct 16, 2025 |
|
The management of CLL in resource-limited settings: guideline development and ongoing projects
|
Oct 16, 2025 |
|
The multi-disciplinary team in CAR-T therapy: insights from a nurse, a neurologist, and a palliative care specialist
|
Sep 29, 2025 |
|
Understanding financial and time toxicity in cancer care: advice for community oncologists
|
Sep 19, 2025 |
|
Listener Q&A special: expert insights on CLL, myeloma, and lymphoma
|
Sep 12, 2025 |
|
Novel strategies and advances in the management and classification of MDS: insights from iwMDS 2025
|
Sep 04, 2025 |
|
Advances in Waldenström’s macroglobulinemia: significance of genetic alterations, current treatment strategies, & ongoing trials
|
Aug 20, 2025 |
|
FLT3-ITD+ AML: recent trial updates, novel approaches, and MRD
|
Aug 15, 2025 |
|
Extramedullary disease in multiple myeloma: biology, management strategies, & the RedirecTT-1 trial
|
Aug 08, 2025 |
|
iwMPN 2025 highlights: novel approaches to the upfront management of myelofibrosis, cardiovascular health in MPNs, & more
|
Aug 01, 2025 |
|
Managing CNS lymphoma: expert insights and updates from ICML 2025
|
Jul 29, 2025 |
|
iwMDS wrap-up: translating research into practice to optimize patient care
|
Jul 18, 2025 |
|
Targeting mutant CALR in MPNs with antibodies & cellular therapy: the potential for disease modification
|
Jul 14, 2025 |
|
Treating elderly or unfit patients with AML: current approach and future directions
|
Jul 04, 2025 |
|
Key HemOnc updates from ASCO 2025: myeloma, lymphoma, MPNs, & more!
|
Jun 30, 2025 |
|
CHIP & CCUS: advances in understanding and should we treat these precursor conditions?
|
Jun 20, 2025 |
|
Diagnosing amyloidosis: identifying early signs, appropriate diagnostic tests, and challenges that remain
|
Jun 14, 2025 |
|
IPIG 2025 Highlights: challenging situations in PNH, updates from the COMMODORE trials, and more
|
Jun 05, 2025 |
|
Recent advances in Hodgkin lymphoma treatment: novel regimens, ongoing trials & treating R/R disease
|
May 30, 2025 |
|
Gene therapy in sickle cell disease: patient selection, potential complications, & more
|
May 23, 2025 |
|
Highlights from iwCAR-T 2025: improving the efficacy and safety of CAR T-cells & access in the community
|
May 19, 2025 |
|
Updates to the ESMO CLL clinical practice guidelines and implications for relapsed therapy
|
May 08, 2025 |
|
Highlights from iwMyeloma 2025: trial updates and practical considerations
|
May 02, 2025 |
|
Updates to the ESMO CLL clinical practice guidelines: implications for frontline treatment
|
Apr 25, 2025 |
|
Highlights from EBMT 2025: preventing and managing GvHD, harnessing AI in transplant, & more
|
Apr 17, 2025 |
|
Sequencing therapies in R/R NHL: immunotherapy in DLBCL, BTKis in MCL, & more!
|
Apr 14, 2025 |
|
Novel CAR strategies being explored in lymphoma: allogeneic products, trispecific CARs & new manufacturing platforms
|
Mar 31, 2025 |
|
Approaches to optimizing induction therapy in AML: FLT3 inhibitors, menin inhibitors, CPX-351, & more!
|
Mar 28, 2025 |
|
Treating R/R mantle cell lymphoma: the role of BTK inhibitors, combination approaches being explored & overcoming resistance
|
Mar 24, 2025 |
|
Addressing unmet needs in myeloma: early detection, frail/elderly patients, triple-class exposed disease, & more!
|
Mar 14, 2025 |
|
CAR T-cell therapy in ALL: trial updates, novel approaches, & real-world outcomes
|
Feb 27, 2025 |
|
Post-ASH amyloidosis highlights: the ANDROMEDA trial, risk stratification, value of MRD, & more!
|
Feb 21, 2025 |
|
Post-ASH non-malignant highlights: updates in sickle cell disease, thalassemia, and hemophilia
|
Feb 14, 2025 |
|
Post-ASH myeloma highlights: key takeaways for community physicians & trials to look out for in 2025
|
Feb 06, 2025 |
|
Post-ASH AML highlights: novel approaches to frontline therapy, advances with menin inhibitors, & managing FLT3-ITD+ AML
|
Jan 31, 2025 |
|
Post-ASH MPN highlights: key trial updates in MF, novel approaches being explored in R/R disease, & more!
|
Jan 28, 2025 |
|
Post-ASH NHL highlights: novel combinations in the frontline setting and advancements with immunotherapy in the R/R setting
|
Jan 24, 2025 |
|
Post-ASH MDS highlights: managing anemia in LR-MDS and novel approaches to treating HR-MDS
|
Jan 17, 2025 |
|
Post-ASH CLL highlights: BTK inhibitors & degraders, bispecific antibodies, & more!
|
Jan 10, 2025 |
|
Advancing treatment for BPDCN: current therapies, a deep dive into tagraxofusp, & emerging novel agents
|
Dec 18, 2024 |
|
Improving care for patients with SCD: pain management, ongoing projects & unmet needs
|
Dec 05, 2024 |
|
Understanding BPDCN: dermatology and hematology perspectives on presentation, diagnosis, treatment, & multidisciplinary care
|
Nov 28, 2024 |
|
Managing complications associated with WM: Bing-Neel syndrome, acquired von Willebrand disease, & more!
|
Nov 19, 2024 |
|
CAR-T therapies and bispecific antibodies in the treatment of high-risk multiple myeloma: updates from iwHRMM 2024
|
Nov 12, 2024 |
|
The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS
|
Nov 06, 2024 |
|
Exploring the role of BTK inhibitors in mantle cell lymphoma: sequencing & managing adverse events
|
Nov 01, 2024 |
|
An update on menin inhibition in AML from iwAL 2024: current data, mechanisms of resistance, & more!
|
Oct 23, 2024 |
|
CAR T-cells and bispecific antibodies in the treatment of NHL: updates from iwNHL 2024
|
Oct 15, 2024 |
|
Prolonging remission in AML: current approaches & future outlooks
|
Oct 08, 2024 |
|
A focus on the use of artificial intelligence to personalize blood cancer care
|
Sep 30, 2024 |
|
A focus on pediatric leukemias: trials, treatments, & challenges
|
Sep 25, 2024 |
|
A focus on the psychosocial impacts of living with blood cancer
|
Sep 18, 2024 |
|
Global perspectives on blood cancers: addressing disparities in awareness, diagnosis, and treatment
|
Sep 09, 2024 |
|
Insights into PV and ET: treating the AYA population, defining goals when treating patients, & more
|
Sep 02, 2024 |
|
Hemophilia updates from ISTH 2024: ongoing clinical trials, emerging gene therapies & remaining challenges
|
Aug 19, 2024 |
|
Inflammation and immune interventions in MDS: targeting STAT, IRAK4, & more
|
Aug 12, 2024 |
|
Updates in the treatment of SCD and thalassemia from EHA 2024: key trial updates, challenges with gene therapies & unmet needs
|
Aug 05, 2024 |
|
Unmet treatment needs in MF: managing prefibrotic disease & thrombocytopenia, novel agents & endpoints for clinical trials
|
Jul 29, 2024 |
|
The role of BTK inhibitors in MCL, ongoing trials & future outlooks: updates from EHA 2024
|
Jul 22, 2024 |
|
Novel developments in lower-risk MDS & important practical considerations when treating patients
|
Jul 15, 2024 |
|
Updates on the use of BCMA-targeting bispecific antibodies in R/R multiple myeloma: insights from EHA & ASCO 2024
|
Jul 08, 2024 |
|
Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more
|
Jul 01, 2024 |
|
Highlights from ISA 2024: the importance of early diagnosis in AL amyloidosis, trials in progress & patient selection for SCT
|
Jun 25, 2024 |
|
Treating LR-MDS beyond ESA failure: currently approved agents, novel approaches & future outlooks
|
Jun 11, 2024 |
|
BPDCN treatment and management: CD123-targeting agents, CNS involvement & approaching pediatric/AYA patients
|
Jun 03, 2024 |
|
The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies
|
May 16, 2024 |
|
iwMyeloma 2024 Session I: approaching bone disease, clinical trial updates & the value of MRD as an endpoint in trials
|
May 10, 2024 |
|
Managing anemia in MF, key emerging trials in the UK, and approaching young patients with MPNs
|
May 03, 2024 |
|
Highlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiome
|
Apr 26, 2024 |
|
The importance of cardio-oncology: awareness around the ESC 2022 guidelines & the value of building MDTs
|
Apr 11, 2024 |
|
Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification
|
Apr 04, 2024 |
|
CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors
|
Mar 28, 2024 |
|
Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception
|
Mar 22, 2024 |
|
The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT
|
Mar 15, 2024 |
|
Diagnosing amyloidosis, currently available therapies & the importance of cardio-oncology
|
Mar 07, 2024 |
|
Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy
|
Feb 29, 2024 |
|
Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks
|
Feb 22, 2024 |
|
Targeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agents
|
Feb 16, 2024 |
|
Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023
|
Feb 08, 2024 |
|
Key updates in thalassemia at ASH 2023: gene therapies, ongoing trials & the value of precision medicine
|
Jan 31, 2024 |
|
Updates, challenges and novel agents being explored in BPDCN
|
Jan 25, 2024 |
|
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets
|
Jan 18, 2024 |
|
Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy
|
Jan 12, 2024 |
|
ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis
|
Jan 05, 2024 |
|
MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF
|
Dec 22, 2023 |
|
iwNHL 2023 Session V: Expanding the CAR platform in NHL
|
Dec 15, 2023 |
|
iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials
|
Dec 07, 2023 |
|
iwNHL 2023 Session IV: Novel therapies in NHL: BTK inhibitors, BTK degraders, and bispecific antibodies
|
Dec 01, 2023 |
|
Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP
|
Nov 24, 2023 |
|
iwNHL 2023 Session III: Recent updates with the use of antibody-drug conjugates in NHL
|
Nov 17, 2023 |
|
MPN diagnosis & treatment: novel agents in PV, clinical guidance for the use of JAK inhibitors & the growing role of combination approaches
|
Nov 10, 2023 |
|
iwNHL 2023 Session II: The evolving treatment landscape in mantle cell lymphoma
|
Nov 03, 2023 |
|
iwNHL 2023 Session I: Updates on the biology and treatment of T-cell lymphoma
|
Oct 27, 2023 |
|
iwAL 2023 Session IV: transplantation and immunotherapies in AML: improving patient outcomes
|
Oct 20, 2023 |
|
Classifying frailty and approaching elderly patients with lymphoma
|
Oct 13, 2023 |
|
Updates on the diagnosis, risk stratification and treatment of lower-risk MDS
|
Oct 06, 2023 |
|
iwAL 2023 Session III: The relevance of TP53 mutation in AML
|
Sep 29, 2023 |
|
iwAL 2023 Session II: Novel treatments in AML: FLT3 inhibitors, combinations, and more
|
Sep 22, 2023 |
|
iwAL 2023 Session I: Clonal hematopoiesis in AML, early detection and potential therapeutics
|
Sep 15, 2023 |
|
Applications of MRD in multiple myeloma: using MRD to guide treatment decisions
|
Sep 08, 2023 |
|
Exploring and comparing the curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL
|
Aug 23, 2023 |
|
Pre-MDS states: improving prognosis, novel therapeutic approaches, and challenges with distinguishing these conditions
|
Aug 16, 2023 |
|
Accelerated-phase MPNs: mutational landscape, challenges, and novel treatment strategies being explored
|
Aug 10, 2023 |
|
Determining the optimal sequencing of bispecifics and CAR-T cells in multiple myeloma
|
Aug 03, 2023 |
|
Overcoming barriers to CAR-T therapy: improving access and cost
|
Jul 27, 2023 |
|
The importance of addressing quality of life and improving symptom management in MPNs
|
Jul 19, 2023 |
|
Updates in the treatment and management of amyloidosis and the importance of the multidisciplinary team
|
Jul 11, 2023 |
|
Hemophilia: the current standard of care and the value of novel gene therapies
|
Jul 05, 2023 |
|
CLL highlights at EHA 2023: latest advances with the use of BTK inhibitors
|
Jun 29, 2023 |
|
Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice
|
Jun 22, 2023 |
|
Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management
|
Jun 16, 2023 |
|
iwCAR-T Session IV: CAR-T therapy in CLL: challenges, combination approaches and ongoing trials
|
Jun 07, 2023 |
|
MDS 2023 highlights: managing anemia in lower-risk MDS & overcoming treatment failure in higher-risk disease
|
May 31, 2023 |
|
iwCAR-T Session III: CAR-T therapy in AML: ongoing challenges and strategies to improve patient outcomes
|
May 24, 2023 |
|
iwCAR-T Session II: CAR-T therapy in ALL: ongoing challenges and future outlooks
|
May 18, 2023 |
|
iwCAR-T Session I: CAR-T therapy in lymphoma and the role of bispecific antibodies
|
May 11, 2023 |
|
iwMyeloma Session III: reaching a cure for multiple myeloma and concepts that need to be addressed
|
May 02, 2023 |
|
The current role of stem cell transplantation in MPNs & how this may change with novel agents
|
Apr 27, 2023 |
|
iwMyeloma Session II: the tumor microenvironment and mechanisms of resistance to targeted therapies
|
Apr 19, 2023 |
|
iwMyeloma Session I: genomics of high-risk and smoldering multiple myeloma
|
Apr 12, 2023 |
|
The important role of transplantation in AML: improving outcomes for patients & the value of pre-transplant MRD
|
Apr 05, 2023 |
|
Insights into the changing role of chemotherapy in lymphoma
|
Mar 31, 2023 |
|
Comparing the ICC and WHO classifications for MDS and their impact on clinical practice
|
Mar 24, 2023 |
|
Managing and treating toxicities associated with CAR-T therapy: CRS, ICANS & infections
|
Mar 16, 2023 |
|
The growing role of immunotherapy in the treatment of ALL & moving away from stem cell transplantation
|
Mar 10, 2023 |
|
The current status of CAR-T therapy in CLL and challenges in this space
|
Mar 03, 2023 |
|
Managing and treating GvHD and other post-transplant complications
|
Feb 23, 2023 |
|
The role of MRD in multiple myeloma
|
Feb 14, 2023 |
|
Novel immune therapies in MDS and challenges in this space
|
Feb 07, 2023 |
|
NHL highlights at ASH 2022: Updates in MCL, the role of transplantation, and novel bispecific antibodies
|
Feb 02, 2023 |
|
MPN highlights at ASH 2022: Novel agents, combinations & the role of immunotherapy
|
Jan 26, 2023 |
|
T-cell lymphoma highlights at ASH 2022: Unmet needs, clinical trial updates & future outlooks
|
Jan 20, 2023 |
|
The importance of CD47 in MDS and other targets of interest
|
Jan 17, 2023 |
|
CLL highlights at ASH 2022: Clinical trial updates, novel BTK inhibitors & combination therapy
|
Jan 09, 2023 |
|
Myeloma highlights at ASH 2022: Improving access to CAR-T therapy & future outlooks
|
Jan 03, 2023 |
|
Highlights in MDS at ASH 2022: Treating lower-risk & higher-risk disease, trial updates, & more
|
Dec 21, 2022 |
|
iwNHL Session V: Novel therapies in NHL - the role of ADCs
|
Dec 16, 2022 |
|
iwAL 2022 Session V: Mechanisms of resistance to targeted therapies in AML
|
Dec 06, 2022 |
|
The importance of genomic testing in CLL and its role in clinical decision-making
|
Dec 02, 2022 |
|
iwNHL Session IV: T-cell therapies for NHL: CAR-T therapies & third-party EBV T-cells
|
Nov 30, 2022 |
|
Key updates in CLL: novel treatment strategies, the changing role of chemotherapy, and more
|
Nov 25, 2022 |
|
iwAL 2022 Session IV: The evolving treatment landscape in ALL and the growing role of immunotherapies
|
Nov 22, 2022 |
|
iwNHL Session III: Exploring the optimal management of R/R follicular lymphoma in an expanding treatment landscape
|
Nov 18, 2022 |
|
iwAL 2022 Session III: Novel targets, combinations and treatment strategies in AML
|
Nov 16, 2022 |
|
Recent updates in CML: treatment strategies, clinical trials, and novel agents
|
Nov 11, 2022 |
|
iwNHL Session II: Understanding and harnessing the immune microenvironment against lymphoma
|
Nov 09, 2022 |
|
iwAL 2022 Session II: Novel treatment strategies in ALL
|
Nov 04, 2022 |
|
The role of the innate immune system in MDS
|
Nov 02, 2022 |
|
iwAL 2022 Session I: The standard of care in AML in 2022
|
Oct 28, 2022 |
|
iwNHL 2022 Session I: Advances in the treatment of T-cell lymphoma
|
Oct 26, 2022 |
|
ISA 2022: meeting highlights and recent updates in amyloidosis
|
Oct 21, 2022 |
|
Highlights from IMS 2022: managing high-risk & frail patients with myeloma and the prognostic value of MRD
|
Oct 13, 2022 |
|
Highlights from the 2022 Texas MPN Workshop: early intervention, disease progression & future targets
|
Oct 07, 2022 |
|
iwMDS 2022: Key highlights
|
Sep 29, 2022 |
|
Identifying high-risk myeloma and improving treatment strategies in these patients
|
Sep 22, 2022 |
|
Improving the efficiency of drug approvals in MDS
|
Sep 14, 2022 |
|
Highlights from the 2022 Texas MPN Workshop: advances in MPN treatment
|
Sep 09, 2022 |
|
The need for more effective first-line therapies in MDS
|
Sep 07, 2022 |
|
Myeloma 2022: day two highlights
|
Sep 02, 2022 |
|
The promise of CAR-T therapy in CLL and challenges in the field
|
Aug 31, 2022 |
|
Clonal hematopoiesis and pre-MDS states
|
Aug 24, 2022 |
|
T-cell engagers in multiple myeloma: current challenges and future outlooks
|
Aug 24, 2022 |
|
High-risk MDS: unmet needs and future treatment approaches
|
Aug 19, 2022 |
|
The importance of patient-reported outcomes in CAR-T recipients
|
Aug 17, 2022 |
|
CAR-T therapy in myeloma and lymphoma
|
Aug 12, 2022 |
|
CAR-T therapy in AML: challenges and future outlooks
|
Aug 10, 2022 |
|
The current state of CAR-T therapy in lymphoma
|
Aug 05, 2022 |
|
Myeloma treatment updates from EHA 2022
|
Aug 03, 2022 |
|
Updates in classification and risk stratification in MDS
|
Jul 27, 2022 |
|
Myeloma 2022: day one highlights
|
Jul 27, 2022 |
|
Immune dysregulation and targeting in MDS
|
Jul 22, 2022 |
|
The future of CAR-T therapy in ALL
|
Jul 20, 2022 |
|
An insight into novel targets in myeloma and mechanisms of resistance to PIs and IMiDs
|
Jul 15, 2022 |
|
Key updates in the treatment and management of MPNs
|
Jul 08, 2022 |